Fibrolamellar Cancer Foundation

The Chan Zuckerberg Initiative (CZI) announced that the Fibrolamellar Cancer Foundation (FCF) is among a select group of patient-led rare disease organizations, including rare cancer foundations, to receive the first CZI 

Founded by Dr. Priscilla Chan and Mark Zuckerberg in 2015, CZI is committing $13.5 million to the 

 to support and lift up the work patient communities are doing to accelerate research and drive progress in the fight against rare diseases, like fibrolamellar carcinoma (Fibrolamellar or FLC). Fibrolamellar is an aggressive, ultra-rare liver cancer affecting children and young adults, with no curative therapies and an alarmingly low five-year survival rate.

"No one is more committed to finding cures for rare diseases than the patients, and families of those affected by these disorders," said Priscilla Chan, Co-Founder & Co-CEO of CZI. "We are proud to support patient-led organizations as they pursue diagnoses, information, and treatment options in partnership with researchers and clinicians."

CZI is providing funding, training, community mentorship, and capacity-building services to assist FCF as it pursues diagnoses, information, and treatment options in partnership with researchers and clinicians.

"Our Foundation has grown tremendously over the past 10 years since it was founded by our son Tucker, before he lost his battle with this cancer," said Marna Davis, Co-Chairman of FCF.

"We're confident that the CZI partnership will spread awareness and help FCF continue to pursue its mission of finding a cure for this disease."

FCF President John Hopper noted, "Recognition and partnership with CZI is an enormous game-changer for the children and young adults fighting rare cancers, such as fibrolamellar, which are too often overlooked. CZI's support will bring much needed global awareness to FLC, and significantly increase the power our patients will have to influence research across academia, industry and government.

Our hope is this will accelerate discoveries of curative therapies, which currently do not exist, to give our young fighters a better chance to survive this cancer."

About the Fibrolamellar Cancer Foundation

The Fibrolamellar Cancer Foundation, Inc. was founded in 2009 by Tucker Davis and his close friends when he was diagnosed with fibrolamellar carcinoma. The purpose of the foundation is to help find a cure and treatment options for this often-fatal disease, raise awareness, and connect and support the fibrolamellar community of patients and their families. 100% of net donations go towards research. For more information, please visit 

Founded by Dr. Priscilla Chan and Mark Zuckerberg in 2015, the Chan Zuckerberg Initiative (CZI) is a new kind of philanthropy that's leveraging technology to help solve some of the world's toughest challenges — from eradicating disease to improving education to reforming the criminal justice system. Across three core Initiative focus areas of Science, Education, and Justice & Opportunity, we're pairing engineering with grant-making, impact investing, and policy and advocacy work to help build an inclusive, just and healthy future for everyone. For more information, please visit 

Articles

The Chan Zuckerberg Initiative (CZI) announced that the Fibrolamellar Cancer Foundation (FCF) is among a select group of patient-led rare disease organizations, including rare cancer foundations, to receive the first CZI Rare As One Network grant.
 

Chan Zuckerberg Initiative Awards Fibrolamellar Cancer Foundation First Ever "Rare As One Network" Grant

" breast cancer awareness month, the Fibrolamellar Cancer Foundation (FCF) reminds the world to think “

” as October is also Liver Cancer Awareness Month.

Fibrolamellar is a very rare form of liver cancer that generally attacks teens and young adults with healthy livers. Sadly, it has a very low survival rate and limited treatment options.

"Unfortunately, there are more types of cancer than there are months of the year," John Hopper, President of the Greenwich-CT based FCF and Co-Chair of the GI Cancers Alliance (GICA) asserted. "Since Fibrolamellar is such a rare and aggressive cancer, Liver Cancer Awareness Month creates an important opportunity to spread the word about the great need for research funding.”

This October, FCF looks to heighten awareness of its 

 logo, in communicating that Fibrolamellar, and all types of cancers, continually need research funding. "Research for treatments or cures for all cancers are a united goal," Hopper said. "We’re all invested in doing everything we can in the battle against cancer."

FCF is a leading funder of rare liver cancer research. Right now, FCF is working with medical and scientific teams at over a dozen prestigious research institutions, as well as the National Cancer Institute (NCI), to seek new treatments. FCF will host its second research gathering, Fibrolamellar Research Summit -

, which will be held in Stamford, Connecticut in early November. This summit will provide an important forum for collaborative exchange amongst some of the world's top rare GI cancer MD’s and PhD’s from academia, industry and government.

FCF, a public 501c3 nonprofit organization based in Greenwich, CT, was founded in 2009 by 27-year-old Tucker Davis, who lost his life to Fibrolamellar in 2010. FCF has funded nearly $7 million in research at major institutions in the U.S. and internationally. With 100% of all donations going to research, all operating costs for the foundation are funded by the Charles A. and Marna Davis Foundation. For more information or to 

 and also interact with us on our social media channels: 

Fibrolamellar Cancer Foundation, 20 Horseneck Lane, 2nd Floor, Greenwich, CT 06830

Fibrolamellar Cancer Foundation

Chan Zuckerberg Initiative Awards Fibrolamellar Cancer Foundation First Ever "Rare As One Network" Grant

Fibrolamellar Cancer Foundation Helps Lead Liver Cancer Awareness Month

Latest News